Chemotherapy with phage lysins reduces pneumococcal colonization of the respiratory tract

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 6, 2018, Pages

  Corsini, Bruno ^a   Díez Martínez, Roberto ^b,d   Aguinagalde, Leire ^a   González Camacho, Fernando ^a   García Fernández, Esther ^b,e   Letrado, Patricia ^b,d   García, Pedro ^b,c,d   Yustea, Jose ^c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Zebrafish Lab   (Spain)

^e CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Mouse model; Nasopharyngeal colonization; Phage lysins; Pneumococcus

Indexed keywords

AMOXICILLIN; CPL 1 LYSIN; CPL 711 LYSIN; CPL 7S LYSIN; ERYTHROMYCIN; HYDROLASE; TETRACYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BACTERIUM ADHERENCE; BACTERIUM ISOLATE; CHEMOTHERAPY; CHIMERA; CONTROLLED STUDY; DRUG EXPOSURE; HUMAN; HUMAN CELL; LUNG EPITHELIUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; WILD TYPE; ANIMAL; DRUG EFFECT; MICROBIOLOGY; PATHOGENICITY; PHARYNX DISEASE; PNEUMOCOCCAL INFECTION; RESPIRATORY SYSTEM;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; MICE; NASOPHARYNGEAL DISEASES; PNEUMOCOCCAL INFECTIONS; RESPIRATORY SYSTEM; STREPTOCOCCUS PNEUMONIAE;

EID: 85047622713     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02212-17     Document Type: Article

References (49)

1. van der Poll T, Opal SM. 2009. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374:1543–1556. https://doi.org/10.1016/S0140-6736(09)61114-4.
2. Koedel U, Scheld WM, Pfister HW. 2002. Pathogenesis and pathophysi-ology of pneumococcal meningitis. Lancet Infect Dis 2:721–736. https://doi.org/10.1016/S1473-3099(02)00450-4.
3. Bogaert D, De Groot R, Hermans PW. 2004. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4:144–154. https://doi.org/10.1016/S1473-3099(04)00938-7.
4. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893–902. https://doi.org/10.1016/S0140-6736(09)61204-6.
5. Sethi S, Murphy TF. 2008. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359:2355–2365. https://doi.org/10.1056/NEJMra0800353.
6. Hermoso JA, Garcia JL, Garcia P. 2007. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr Opin Microbiol 10:461–472. https://doi.org/10.1016/j.mib.2007.08.002.
7. Pastagia M, Schuch R, Fischetti VA, Huang DB. 2013. Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol 62:1506–1516. https://doi.org/10.1099/jmm.0.061028-0.
8. Blázquez B, Fresco-Taboada A, Iglesias-Bexiga M, Menéndez M, García P. 2016. PL3 amidase, a tailor-made lysin constructed by domain shuffling with potent killing activity against pneumococci and related species. Front Microbiol 7:1156. https://doi.org/10.3389/fmicb.2016.01156.
9. Díez-Martínez R, de Paz HD, Bustamante N, García E, Menéndez M, García P. 2013. Improving the lethal effect of cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module. Antimicrob Agents Chemother 57: 5355–5365. https://doi.org/10.1128/AAC.01372-13.
10. Díez-Martínez R, De Paz HD, García-Fernández E, Bustamante N, Euler CW, Fischetti VA, Menéndez M, García P. 2015. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. J Antimicrob Chemother 70:1763–1773. https://doi.org/10.1093/jac/dkv038.
11. Verbree CT, Datwyler SM, Meile S, Eichenseher F, Donovan DM, Loessner MJ, Schmelcher M. 2017. Identification of peptidoglycan hydrolase constructs with synergistic staphylolytic activity in cow’s milk. Appl Environ Microbiol 83:e03445-16. https://doi.org/10.1128/AEM.03445-16.
12. Jado I, López R, García E, Fenoll A, Casal J, García P, Spanish Pneumococcal Infection Study Network. 2003. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 52:967–973. https://doi.org/10.1093/jac/dkg485.
13. Grandgirard D, Loeffler JM, Fischetti VA, Leib SL. 2008. Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis 197:1519–1522. https://doi.org/10.1086/587942.
14. Witzenrath M, Schmeck B, Doehn JM, Tschernig T, Zahlten J, Loeffler JM, Zemlin M, Muller H, Gutbier B, Schutte H, Hippenstiel S, Fischetti VA, Suttorp N, Rosseau S. 2009. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit Care Med 37:642–649. https://doi.org/10.1097/CCM.0b013e31819586a6.
15. Loeffler JM, Djurkovic S, Fischetti VA. 2003. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 71: 6199–6204. https://doi.org/10.1128/IAI.71.11.6199-6204.2003.
16. Kadioglu A, Weiser JN, Paton JC, Andrew PW. 2008. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 6:288–301. https://doi.org/10.1038/nrmicro1871.
17. Desai AP, Sharma D, Crispell EK, Baughman W, Thomas S, Tunali A, Sherwood L, Zmitrovich A, Jerris R, Satola SW, Beall B, Moore MR, Jain S, Farley MM. 2015. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J 34:1168–1174. https://doi.org/10.1097/INF.0000000000000849.
18. Valente C, Hinds J, Gould KA, Pinto FR, de Lencastre H, Sa-Leao R. 2016. Impact of the 13-valent pneumococcal conjugate vaccine on Streptococcus pneumoniae multiple serotype carriage. Vaccine 34:4072–4078. https://doi.org/10.1016/j.vaccine.2016.06.017.
19. Sánchez-Tatay D, Arroyo LA, Tarragó D, Lirola MJ, Porras A, Fenoll A, Hausdorff WP, Brueggemann AB, Obando I. 2008. Antibiotic susceptibility and molecular epidemiology of nasopharyngeal pneumococci from Spanish children. Clin Microbiol Infect 14:797–801. https://doi.org/10.1111/j.1469-0691.2008.02025.x.
20. Domenech A, Ardanuy C, Calatayud L, Santos S, Tubau F, Grau I, Verda-guer R, Dorca J, Pallares R, Martin R, Linares J. 2011. Serotypes and genotypes of Streptococcus pneumoniae causing pneumonia and acute exacerbations in patients with chronic obstructive pulmonary disease. J Antimicrob Chemother 66:487–493. https://doi.org/10.1093/jac/dkq480.
21. Pérez-Trallero E, Marimón JM, Larruskain J, Alonso M, Ercibengoa M. 2011. Antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae isolates from elderly patients with pneumonia and acute exacerbation of chronic obstructive pulmonary disease. Antimicrob Agents Chemother 55:2729 –2734. https://doi.org/10.1128/AAC.01546-10.
22. Fischetti VA. 2008. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 11:393–400. https://doi.org/10.1016/j.mib.2008.09.012.
23. McCullers JA, Karlstrom A, Iverson AR, Loeffler JM, Fischetti VA. 2007. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog 3:e28. https://doi.org/10.1371/journal.ppat.0030028.
24. Cheng Q, Nelson D, Zhu S, Fischetti VA. 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 49:111–117. https://doi.org/10.1128/AAC.49.1.111-117.2005.
25. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294: 2170–2172. https://doi.org/10.1126/science.1066869.
26. Domenech M, García E, Moscoso M. 2011. In vitro destruction of Streptococcus pneumoniae biofilms with bacterial and phage peptidoglycan hydrolases. Antimicrob Agents Chemother 55:4144–4148. https://doi.org/10.1128/AAC.00492-11.
27. Nelson D, Loomis L, Fischetti VA. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci U S A 98:4107–4112. https://doi.org/10.1073/pnas.061038398.
28. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroedan F, Bouvenot G, Eschwege E. 1998. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279:365–370. https://doi.org/10.1001/jama.279.5.365.
29. Schrag SJ, Pena C, Fernandez J, Sanchez J, Gomez V, Perez E, Feris JM, Besser RE. 2001. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286:49–56. https://doi.org/10.1001/jama.286.1.49.
30. Ghaffar F, Muniz LS, Katz K, Reynolds J, Smith JL, Davis P, Friedland IR, McCracken GH, Jr. 2000. Effects of amoxicillin/clavulanate or azithromy-cin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. Clin Infect Dis 31:875–880. https://doi.org/10.1086/318160.
31. Mwenya DM, Charalambous BM, Phillips PP, Mwansa JC, Batt SL, Nunn AJ, Walker S, Gibb DM, Gillespie SH. 2010. Impact of co-trimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia. Antimicrob Agents Chemother 54:3756–3762. https://doi.org/10.1128/AAC.01409-09.
32. Iwanaga N, Nakamura S, Oshima K, Kajihara T, Takazono T, Miyazaki T, Izumikawa K, Yanagihara K, Sugawara A, Sunazuka T, Omura S, Kohno S. 2015. Macrolides promote CCL2-mediated macrophage recruitment and clearance of nasopharyngeal pneumococcal colonization in mice. J Infect Dis 212:1150–1159. https://doi.org/10.1093/infdis/jiv157.
33. Marks LR, Clementi EA, Hakansson AP. 2012. The human milk protein-lipid complex HAMLET sensitizes bacterial pathogens to traditional antimicrobial agents. PLoS One 7:e43514. https://doi.org/10.1371/journal.pone.0043514.
34. Rankine-Mullings AE, Owusu-Ofori S. 2017. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev 10:CD003427. https://doi.org/10.1002/14651858.CD003427.pub4.
35. Turley AJ, Gathmann B, Bangs C, Bradbury M, Seneviratne S, Gonzalez-Granado LI, Hackett S, Kutukculer N, Alachkar H, Hambleton S, Ritter-busch H, Kralickova P, Marodi L, Seidel MG, Dueckers G, Roesler J, Huissoon A, Baxendale H, Litzman J, Arkwright PD. 2015. Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol 35:199 –205. https://doi.org/10.1007/s10875-015-0137-5.
36. Esposito S, Terranova L, Patria MF, Marseglia GL, Miraglia Del Giudice M, Bodini A, Martelli A, Baraldi E, Mazzina O, Tagliabue C, Licari A, Ierardi V, Lelii M, Principi N. 2016. Streptococcus pneumoniae colonisation in children and adolescents with asthma: impact of the heptavalent pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-valent pneumococcal conjugate vaccine. BMC Infect Dis 16:12. https:// doi.org/10.1186/s12879-016-1335-3.
37. Principi N, Preti V, Gaspari S, Colombini A, Zecca M, Terranova L, Cefalo MG, Ierardi V, Pelucchi C, Esposito S. 2016. Streptococcus pneumoniae pharyngeal colonization in school-age children and adolescents with cancer. Hum Vaccin Immunother 12:301–307. https://doi.org/10.1080/21645515.2015.1090071.
38. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF. 2000. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 342: 681–689. https://doi.org/10.1056/NEJM200003093421002.
39. Almirall J, Bolíbar I, Serra-Prat M, Roig J, Hospital I, Carandell E, Agusti M, Ayuso P, Estela A, Torres A, Community-Acquired Pneumonia in Catalan Countries Study Group. 2008. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 31:1274–1284. https://doi.org/10.1183/09031936.00095807.
40. Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J. 2014. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis 59:615–623. https://doi.org/10.1093/cid/ciu348.
41. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. 2014. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 1:ofu024. https://doi.org/10.1093/ofid/ofu024.
42. Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. 2014. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol 52:2813–2823. https://doi.org/10.1128/JCM.00035-14.
43. Martin C, Burgel PR, Lepage P, Andrejak C, de Blic J, Bourdin A, Brouard J, Chanez P, Dalphin JC, Deslee G, Deschildre A, Gosset P, Touqui L, Dusser D. 2015. Host-microbe interactions in distal airways: relevance to chronic airway diseases. Eur Respir Rev 24:78–91. https://doi.org/10.1183/09059180.00011614.
44. Abedon ST. 2015. Phage therapy of pulmonary infections. Bacteriophage 5:e1020260. https://doi.org/10.1080/21597081.2015.1020260.
45. Ramos-Sevillano E, Rodríguez-Sosa C, Díez-Martínez R, Giménez MJ, Olmedillas E, García P, García E, Aguilar L, Yuste J. 2012. Macrolides and beta-lactam antibiotics enhance C3b deposition on the surface of multidrug-resistant Streptococcus pneumoniae strains by a LytA autolysin-dependent mechanism. Antimicrob Agents Chemother 56: 5534–5540. https://doi.org/10.1128/AAC.01470-12.
46. Ramos-Sevillano E, Moscoso M, García P, García E, Yuste J. 2011. Nasopharyngeal colonization and invasive disease are enhanced by the cell wall hydrolases LytB and LytC of Streptococcus pneumoniae. PLoS One 6:e23626. https://doi.org/10.1371/journal.pone.0023626.
47. Morey P, Cano V, Martí-Lliteras P, López-Gómez A, Regueiro V, Saus C, Bengoechea JA, Garmendia J. 2011. Evidence for a non-replicative intracellular stage of nontypable Haemophilus influenzae in epithelial cells. Microbiology 157:234–250. https://doi.org/10.1099/mic.0.040451-0.
48. Ramos-Sevillano E, Urzainqui A, Campuzano S, Moscoso M, González-Camacho F, Domenech M, Rodríguez de Córdoba S, Sánchez-Madrid F, Brown JS, García E, Yuste J. 2015. Pleiotropic effects of cell wall amidase LytA on Streptococcus pneumoniae sensitivity to the host immune response. Infect Immun 83:591–603. https://doi.org/10.1128/IAI.02811-14.
49. Ramos-Sevillano E, Urzainqui A, de Andrés B, González-Tajuelo R, Domenech M, González-Camacho F, Sánchez-Madrid F, Brown JS, García E, Yuste J. 2016. PSGL-1 on leukocytes is a critical component of the host immune response against invasive pneumococcal disease. PLoS Pathog 12:e1005500. https://doi.org/10.1371/journal.ppat.1005500.